For the quarter ending 2025-12-31, IBIO had $561K increase in cash & cash equivalents over the period. -$5,757K in free cash flow.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | -8,993 | -5,720 | -18,377 |
| Share-based compensation | 253 | 323 | 1,530 |
| Amortization of intangible assets | 5 | 5 | 20 |
| Amortization of finance lease right-of-use assets | 0 | 68 | 271 |
| Amortization of operating lease right-of-use assets | 95 | 93 | 351 |
| Depreciation of fixed assets | 141 | 123 | 484 |
| Accrued interest receivable on promissory note receivable | 20 | 19 | 62 |
| Amortization of premiums/(accretion of discounts) on debt securities | 79 | 9 | - |
| Provision for credit losses | 65 | - | - |
| Impairment of intangible assets | 2,500 | - | - |
| Accounts receivable - trade | 0 | 65 | - |
| Prepaid expenses and other current assets | -360 | 106 | 408 |
| Security deposit | -16 | - | - |
| Accounts payable | -29 | 495 | 1,831 |
| Accrued expenses | 567 | -686 | -758 |
| Operating lease obligations | -122 | -117 | -436 |
| Contract liabilities | 0 | -50 | 250 |
| Net cash used in operating activities | -5,241 | -5,665 | -15,304 |
| Payment received for interest and principal on promissory note receivable | - | - | 758 |
| Purchases of debt securities | 2,467 | 21,461 | - |
| Purchases of fixed assets | 516 | 32 | 16 |
| Net cash (used in) provided by investing activities | -2,983 | -21,493 | 742 |
| Proceeds from sales of common stock | 0 | 219 | 3,541 |
| Proceeds from sales of pre-funded warrants | 55,948 | - | - |
| Proceeds from pre-funded warrants | - | 50,006 | 6,246 |
| Proceeds from the exercise of warrants | 3,651 | - | - |
| Payments made for costs to acquire capital | 194 | 3,465 | 294 |
| Proceeds from the exercise of stock options | - | - | 131 |
| Subscription receivable | 0 | 105 | - |
| Payment of equipment financing loan | 17 | 47 | 178 |
| Payment of term promissory note | 597 | 60 | 218 |
| Payment of finance lease obligation | 0 | 53 | 299 |
| Net cash provided by (used in) financing activities | 8,785 | 46,705 | 8,929 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 561 | 19,547 | -5,633 |
| Cash and cash equivalents at beginning of period | 28,339 | 8,792 | - |
| Cash and cash equivalents at end of period | 28,900 | 28,339 | - |
iBio, Inc. (IBIO)
iBio, Inc. (IBIO)